Introduction {#s1}
============

Currently prescribed antidepressant drugs are not effective in all patients and often take weeks before the therapeutic benefit is realized ([@CIT0024]). Recently, N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine, have been examined for antidepressant efficacy. A single subanesthetic dose of ketamine has been shown to reduce symptoms of depression in rodents on the forced swim test (FST) ([@CIT0001]; [@CIT0011]) and in humans suffering from treatment-resistant depression ([@CIT0005]; [@CIT0026]). Importantly, the therapeutic effect begins almost immediately and can persist in patients for up to 2 weeks ([@CIT0020]). Despite its promise, the mechanism of ketamine's antidepressant effect has not been completely elucidated ([@CIT0019]).

We recently demonstrated that activation of a ventral hippocampus (vHipp)--medial prefrontal cortex (mPFC) pathway is both necessary and sufficient for an antidepressant response to ketamine ([@CIT0011]). Indeed, this is consistent with the work of others demonstrating altered synaptic transmission in the mPFC is associated with the antidepressant action of ketamine ([@CIT0015]; [@CIT0001]). To explain the seemingly contradictory finding that blocking the activity of an excitatory neurotransmitter would drive activity in the vHipp-mPFC pathway, it has been proposed that ketamine selectively antagonizes NMDA receptors on inhibitory interneurons, causing disinhibition of pyramidal cells ([@CIT0019]). The reason why ketamine may preferentially target GABAergic interneurons relates to the physiological blockade of the NMDA receptor by Mg^2+^. Although NMDA receptors are ligand gated, they are also voltage dependent. Thus, at the resting potential of pyramidal neurons NMDA receptors are nearly completely blocked by Mg^2+^ ([@CIT0021]). In contrast, the fast-firing GABAergic interneurons are more depolarized and therefore less susceptible to Mg^2+^ blockade. Indeed, ketamine has been shown to selectively suppress the spiking activity of putative fast-spiking interneurons ([@CIT0022]). Thus, we posit that ketamine produces an antidepressant response by decreasing interneuron function in the hippocampus, leading to an augmented glutamatergic drive to the prefrontal cortex.

To target hippocampal interneurons selectively, we degraded the extracellular matrix surrounding fast-firing parvalbumin (PV)-containing interneurons known as a perineuronal net (PNN). PNNs are chondroitin sulfate proteoglycans that form an extracellular matrix around PV-containing interneurons ([@CIT0012]). The PNN is thought to play an important role in the function of PV-containing interneurons. For example, PNNs can act to stabilize synapses ([@CIT0004]), support synaptic plasticity ([@CIT0009]; [@CIT0007]; [@CIT0006]), regulate motility of extracellular ions ([@CIT0008]; [@CIT0014]), and protect fast-spiking interneurons against oxidative stress ([@CIT0010]). Therefore, in the current experiments, we hypothesized that enzymatic degradation of PNNs surrounding PV-containing interneurons of the vHipp would attenuate the antidepressant effect of ketamine.

Methods {#s2}
=======

Animals {#s3}
-------

Adult male Sprague-Dawley rats (Harlan, 250--275 g at the time of arrival) were used for all experiments. Animals were maintained in a temperature-controlled environment on a 14:10-h light-dark cycle and had access to food and water ad libitum. All procedures were consistent with NIH guidelines (NIH publications no. 80-23, revised 1978) and approved by the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio.

Chondroitinase Treatment {#s4}
------------------------

To degrade PNNs, animals were anesthetized (sodium pentobarbital, 60 mg/kg, i.p.) and placed into a stereotaxic apparatus. Bilateral cannula aimed at the vHipp (A/P -5.3, M/L ±5.2, DV -7.5 mm from bregma) were used to inject 0.75 μL of chondroitinase ABC from *Proteus vulgaris* (0.05 U μL^-1^). Penicillinase from *Bacillus cereus* (0.05 U μL^-1^), a nonrelevant enzyme, was used as a control, as published previously ([@CIT0023]). Rats were allowed at least 1 week to recover before testing.

FST {#s5}
---

To measure the antidepressant effects of ketamine, the FST was used as previously reported ([@CIT0011]). Briefly, rats were placed into a plexiglass cylinder (21 x 46 cm) filled with water (25°C) for 5 min while behavior was digitally recorded for offline analysis. Rats were tested either 30 min or 1 week following a single administration of ketamine (Sigma, 10 mg/kg, i.p). To analyze the behavior, a time-sampling technique was used in which the most prominent behavior (immobility, swimming, climbing) observed was recorded in each 5-second bin. All videos were scored blind.

Histochemistry {#s6}
--------------

To confirm the loss of PNNs, rats were transcardially perfused with saline, followed by formaldehyde, and brains were postfixed and cryopreserved for at least 24 hours. Coronal sections (50 μm) through the vHipp were blocked (2% normal goat serum), incubated with lectin from *Wisteria floribunda* (4 μg mL^-1^), then AlexaFluor594 conjugated to streptavidin. A subset of sections was also incubated with a rabbit anti-PV antibody (Abcam:AB11427), then anti-rabbit AlexaFluor488. Sections were mounted and coverslipped with Prolong Gold Antifade reagent (Molecular Probes). The representative images were acquired using an Olympus IX81 Motorized inverted confocal microscope and FV10-ASW software and enhanced using ImageJ.

Analysis {#s7}
--------

FST data were analyzed by 2-way ANOVA followed by the Holm-Sidak posthoc method. All tests were 2-tailed, and significance was determined at *P*\<.05. In all figures, data are shown as mean ± SEM and n is indicated in the figure legend.

Results {#s8}
=======

FST {#s9}
---

The FST was used to measure the acute and chronic antidepressant effect of ketamine 30 minutes or 1 week after drug administration, respectively. As we have shown previously, as soon as 30 minutes after administration, ketamine produces an antidepressant effect on the FST. Thirty minutes after ketamine administration, there was a decrease in immobility ([Figure 1A](#F1){ref-type="fig"}; Saline/Pen=38.44±2.38, Ketamine/Pen 30.11±2.38; 2-way ANOVA: interaction F~(1,33)~ = 0.007, drug F~(1,33)~ = 12.18, enzyme F~(1,33)~ = 2.22; Holm-Sidak: t=2.48, *P*=.02). The effect of ketamine on immobility was present even when PNNs were degraded (Saline/Chon = 35.00 ± 2.52, Ketamine/Chon = 26.25 ± 2.52, Holm-Sidak: t = 2.46, *P*=.02). This effect was driven primarily by an increase in swimming that was observed 30 minutes after ketamine administration in both penicillinase- and chondroitinase-treated animals ([Figure 1B](#F1){ref-type="fig"}; Saline/Pen =10.89 ± 2.65, Ketamine/Pen=19.22±2.65, Saline/Chon=10.88±2.81, Ketamine/Chon=17.88±2.81; 2-way ANOVA: interaction F~(1,33)~=0.06, drug F~(1,33)~=7.87, enzyme F~(1.33)~=0.06; Holm-Sidak: t=2.22, *P*=.034). We also found that chondroitinase itself increased climbing behavior ([Figure 1C](#F1){ref-type="fig"}; Saline/Pen=10.67±1.69, Ketamine/Pen=10.56±1.69, Saline/Chon=14.13 ± 1.80, Ketamine/Chon=15.88±1.80; 2-way ANOVA: interaction F~(1,33)~ = 0.28, drug F~(1,33)~ = 0.22, enzyme F~(1.33)~=6.32; Holm-Sidak: t=2.52, *P*=.02). Together, these results suggest that the acute antidepressant effect of ketamine is not dependent on PNN function.

![Perineuronal nets (PNNs) are required for the sustained but not acute antidepressant effect of ketamine. Thirty minutes after ketamine injection, both penicillinase- and chondroitinase-treated animals show a significant reduction in immobility (A) and an increase in swimming (B) compared with saline-treated control animals. Chondroitinase treatment itself produced an increase in climbing (C). One week after ketamine injection, penicillinase-treated animals continue to show reductions in immobility (D) and increases in swimming (E). This sustained antidepressant effect is abolished in the rats treated with chondroitinase in the vHipp. There was no significant effect on climbing when animals were tested one week after ketamine injection (F). \*Significantly different than the corresponding saline control; +significantly different than penicillinase/ketamine. Chondroitinase n=8/group. Penicillinase n=9/group.](pyw09501){#F1}

Interestingly, when animals were subjected to a second swim 1 week later, we found a different effect. Again, in penicillinase-treated animals, ketamine reduced immobility time ([Figure 1D](#F1){ref-type="fig"}; Saline/Pen =35.22±2.98, Ketamine/Pen=23.67±2.98; 2-way ANOVA: interaction F~(1,33)~ =2.748, drug F~(1,33)~ =4.43, enzyme F~(1,33)~=0.32; Holm-Sidak: t=2.74, *P*=.01). However, in the rats that received chondroitinase to degrade PNNs in the vHipp, ketamine had no effect on immobility time (Saline/Chon = 31.88 ± 3.16, Ketamine/Chon = 30.50 ± 3.16; Holm-Sidak: t=0.31, *P*=.76). This effect was driven primarily by an increase in swimming time that was observed in the penicillinase-treated animals ([Figure 1E](#F1){ref-type="fig"}; Saline/Pen =19.22±2.59, Ketamine/Pen = 29.33 ± 2.59; 2-way ANOVA: interaction F~(1,33)~=6.27, drug F~(1,33)~=1.65, enzyme F~(1,33)~=1.29; Holm-Sidak: t=2.76, *P*=.01), but not in the chondroitinase-treated rats (Saline/Chon = 22.88 ± 2.75, Ketamine/Chon = 19.63 ± 2.75; Holm-Sidak: t= 0.84, *P*=.41). One week after ketamine treatment, we did not observe significant changes in climbing behavior in response to any treatment ([Figure 1F](#F1){ref-type="fig"}; Saline/Pen=5.56±1.52, Ketamine/Pen = 7.00 ± 1.52, Saline/Chon = 5.25 ± 1.61, Ketamine/Chon = 9.88 ± 1.61; 2-way ANOVA: interaction F~(1,33)~ = 1.04, drug F~(1,33)~ = 3.77, enzyme F~(1,33)~=0.68). Together, these results suggest that PNNs are required for the sustained antidepressant effect of ketamine.

Histochemistry {#s10}
--------------

Dual florescence immunohistochemistry was used to confirm that PNNs surround PV-positive cells in the vHipp. Representative images are shown in [Figure 2A](#F2){ref-type="fig"}-[C](#F2){ref-type="fig"}. Further, immunohistochemistry was also used to confirm that chondroitinase injection produced a region specific reduction in PNNs ([Figure 2D](#F2){ref-type="fig"}-[I](#F2){ref-type="fig"}). In the penicillinase-treated rats, PNNs were observed throughout the vHipp ([Figure 2D](#F2){ref-type="fig"},F) and in cortical areas ([Figure 2H](#F2){ref-type="fig"}). Chondroitinase injection in the vHipp reduced PNNs in this region ([Figure 2E](#F2){ref-type="fig"},G). PNNs were still observed in more dorsal cortical regions of chondroitinase-treated rats ([Figure 2I](#F2){ref-type="fig"}), suggesting that the chondroitinase injection produced a region specific loss of PNNs.

![Chondroitinase degrades perineuronal nets (PNNs) surrounding parvalbumin (PV)-positive interneurons. A-C show high magnification PNNs surrounding PV cells. D and E depict a representative hippocampal section from a penicillinase- and chondroitinase-treated animal, respectively. Penicillinase-treated animals display PNNs in the ventral hippocampus (vHipp) (dashed box in D is magnified in F) as well as in other cortical areas (solid box in D is magnified in H). Chondroitinase injection caused a region-specific reduction of PNNs in the vHipp (dashed box in E is magnified in G) but not in more dorsal areas of the cortex (solid box in E is magnified in I). The diffusion area of the injection is shown in E by a solid circle. Block arrows indicate PV-positive cells, line arrows indicate PNNs, arrowheads indicate PV-positive cells surrounded by PNNs. Green, PV; red, PNNs. Scale bar = 50 μ.](pyw09502){#F2}

Discussion {#s11}
==========

Here we demonstrate that PNNs in the vHipp are required for the sustained, but not the acute, antidepressant effect of ketamine. Ketamine is an antagonist at the NMDA family of glutamate receptors; however, low doses of ketamine enhance excitatory input to corticolimbic brain regions, which is thought to underlie its antidepressant effect ([@CIT0010]). Two primary hypotheses have been proposed to understand how blockade of excitatory glutamate receptors would produce an excitatory effect. First, it has been shown that at low doses, ketamine selectively antagonizes NMDA receptors on inhibitory interneurons, allowing disinhibition of pyramidal cells ([@CIT0022]). Ketamine has been shown to temporarily reduce expression of PV and the GABA-producing enzyme, GAD, further supporting the hypothesis that this drug reduces the function of inhibitory interneurons ([@CIT0002]; [@CIT0027]). Alternatively, it has been suggested that ketamine acts directly on pyramidal cells, inducing protein synthesis and causing a cell-autonomous form of synaptic plasticity such that the cells receive enhanced excitatory input ([@CIT0019]). It should be noted that a recent publication suggested that the sustained antidepressant response of ketamine may be mediated by the ketamine metabolite, (2R, 6R)-HNK, which activates AMPA receptors and induces excitation in both pyramidal cells and interneurons of the hippocampus ([@CIT0025]). Nonetheless, our results demonstrate that the ketamine-induced increase in immobility on the FST is blocked by the degradation of perienuronal nets surrounding fast-spiking interneurons in the vHipp and supports the hypothesis that inhibitory interneurons play an important role in the sustained antidepressant activity of ketamine.

In the current experiments, we targeted PNNs specifically in the vHipp, a brain region that we have shown previously to be important for the sustained, but not acute, effect of ketamine ([@CIT0011]). Specifically, we have previously demonstrated that vHipp inactivation at the time of ketamine administration blocks the decrease in immobility in the FST seen at 1 week but not 30 minutes after ketamine ([@CIT0011]). Further, we demonstrated that activation of hippocampal projection neurons specifically to the mPFC were both necessary and sufficient for the sustained antidepressant effect of ketamine ([@CIT0011]). This finding is consistent with the work of others demonstrating that changes in synaptic function occur in the mPFC after ketamine administration ([@CIT0015]; [@CIT0001]). In the current study, we blocked the sustained antidepressant effect of ketamine by enzymatically degrading PNNs in the vHipp. We hypothesize that this manipulation is disrupting the function of PV interneurons that regulate activity of pyramidal cells that project to the prefrontal cortex.

In addition to its connections to the mPFC, the vHipp has also been shown to regulate dopamine cells in the ventral tegmental area via a polysynaptic pathway beginning in the nucleus accumbens (NAc) ([@CIT0017]). Interestingly, activity in this vHipp-NAc projection is correlated with the antidepressant response to ketamine ([@CIT0003]). However, using designer receptors exclusively activated by designer drugs, we have shown that while activation of the vHipp-mPFC pathway produces an antidepressant-like response, activation of the vHipp-NAc pathway has no effect on the FST in unstressed rats ([@CIT0011]). Thus, it is possible that the vHipp-NAc-VTA pathway may be recruited in situations that involve stress, such as the learned helplessness paradigm, or may contribute to symptoms of depression not measured by the FST, such as anhedonia.

In the current experiments, we demonstrated that PNNs in the hippocampus are required for the sustained antidepressant effect of ketamine. Although PNNs have been shown to recover after chondroitinase treatment, we found that the nets were not present even at the time of the second swim test ([Figure 2](#F2){ref-type="fig"}). It has been shown previously that PNNs can influence the function of PV cells through a variety of mechanisms. For example, removal of the PNNs in the hippocampus reduces long-term potentiation ([@CIT0009]; [@CIT0007]), suggesting that this form of extracellular matrix plays an important role in regulating synaptic plasticity. As described above, we have shown previously that the sustained antidepressant effect of ketamine requires plasticity in the vHipp-mPFC pathway ([@CIT0011]). Therefore, we hypothesize that ablation of PNNs in the vHipp prevents this plasticity from occurring and ultimately abolishes the sustained but not acute antidepressant effect of ketamine. Further, PNNs have also been shown to attract maintenance factors like BDNF to PV cells ([@CIT0013]). Interestingly, we and others have demonstrated that the sustained antidepressant response to ketamine is dependent on BDNF ([@CIT0001]; [@CIT0016]; [@CIT0011]). Specifically, ketamine increases phosphorylation of the BDNF receptor, TrkB, in the vHipp ([@CIT0011]). Furthermore, injection of K252a, a tyrosine kinase inhibitor, into the vHipp at the time of ketamine administration prevented the chronic antidepressant effect of ketamine ([@CIT0011]). These results suggest that ablation of PNNs may prevent the sustained antidepressant effect of ketamine by reducing neurotrophin signaling; again, this remains to be elucidated.

In conclusion, the current experiments demonstrate that PNNs, the specialized extracellular matrix that surround PV cells in the vHipp, are necessary for the sustained antidepressant response to ketamine. Disruptions in the extracellular matrix have been observed in patients with psychiatric disorders such as depression and schizophrenia ([@CIT0018]). Therefore, understanding the role of PNNs in the antidepressant action of ketamine may have important implications for this novel and promising antidepressant drug.
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